INmune Bio Inc.

INmune Bio Inc.

INMBNYSE / NASDAQHealthcareSmall cap

$0.83-$0.07 (-7.5%)

Last close · Data as of Nov 20, 2026

Market cap
$35.9M
P/E
-0.8x
EV / EBITDA
-0.4x
Revenue
$50.0k
Net margin
-91866.0%
ROCE
-129.0%

-44.5% over the last year

INmune Bio Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-48.3%
3M
-61.7%
6M
-41.3%
1Y
-44.5%
5Y
Hidden
  • This period includes a one-day price step on 30 Jun 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.07 (-7.5%) from $0.89 to $0.83 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in INMB, bought on each weekday since 2021.

News & filings

What INmune Bio filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 45.9 million US dollars in fiscal 2025.

Strengths (1)

  • Cash on the balance sheet equals 69% of the company's market value.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

Read moreShow less

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Sector
Healthcare
Shares outstanding
26.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$35.9M
P/E
-0.8x
P/B
1.5x
EV / EBITDA
-0.4x
EV / Sales
243.5x
P/S
717.8x
52-week high
$2.51
52-week low
$0.83

Profitability

Operating margin
-61738.0%
Net margin
-91866.0%
EBITDA margin
-61570.0%
ROE
-195.3%
ROCE
-129.0%
ROA
-142.0%
Asset turnover
0.00

Growth

Revenue
$50.0k
Revenue growth, 1Y
257.1%
Revenue CAGR, 3Y
-48.9%
Net profit growth, 1Y
9.2%
Free cash flow
-$23.6M

Solvency

Current ratio
3.55
Debt / Equity
0.04
Debt / Assets
0.03
CFO / Net profit
0.49
Cash / Market cap
69.0%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$50.0k
Gross profit$50.0k
Operating expenses$30.9M
Research and development$20.7M
Selling, general and administrative$10.3M
Operating income-$30.9M
Interest and other-$15.1M
Pretax income-$45.9M
Tax and other$0.00
Net income-$45.9M

Revenue and net profit

Revenue grew 257.1% in FY2025; net profit is the dashed line.

INmune Bio Inc. revenue and net profit by fiscal year
INmune Bio Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$374.0k-$27.3M
FY2023$155.0k-$30.0M
FY2024$14.0k-$42.1M
FY2025$50.0k-$45.9M

Cash flows

FY2025: -$22.6M from operations, -$23.6M free after investment (dashed).

INmune Bio Inc. operating and free cash flow by fiscal year
INmune Bio Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$22.7M-$22.7M
FY2023-$12.0M-$12.0M
FY2024-$33.4M-$33.4M
FY2025-$22.6M-$23.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$50.0k+257.1%1Y
EBITDA
-$30.8M
Net profit
-$45.9M
Cash from operations
-$22.6M
Free cash flow
-$23.6M
Revenue CAGR, 3Y
-48.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$50.0k-$30.8M-$45.9M-$23.6M-195.3%+257.1%+9.2%

Monthly returns

Month-by-month returns of INMB across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$32.4M
Liabilities$8.8M
Equity$23.5M
Paid-in capital$233.3M
Retained earnings-$209.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; INMB highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. INmune Bio Inc. (this company)243.5x

Not shown (no positive earnings and no EV / Sales): Actuate Therapeutics, Inc. Common stock, Tevogen Bio Holdings Inc., Tvardi Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
INmune Bio Inc.INMBthis company$35.9M-0.8x1.5x-195.3%-0.4x
DocGo Inc.DCGO$56.3M-0.3x0.4x-126.7%-0.5x
aTyr Pharma, Inc.ATYR$50.3M-0.7x0.7x-109.8%-0.7x
Myomo, Inc.MYO$49.8M-3.2x4.4x-136.6%-4.4x
Actuate Therapeutics, Inc. Common stockACTU$46.4M-2.1x5.9x-280.5%—
Accuray IncorporatedARAY$43.5M-27.3x0.5x-2.0%8.0x
Gossamer Bio, Inc.GOSS$41.7M-0.2x-0.3x138.8%-1.3x
Tevogen Bio Holdings Inc.TVGN$41.3M-1.6x-2.4x154.2%-1.9x
Tvardi Therapeutics, Inc.TVRD$28.9M-1.6x1.4x-87.0%-0.3x
Peer median—-1.6x0.6x-98.4%-0.7x

Year-to-date ROI

INMB since 1 January, against earlier years.

Historical volatility

INMB's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

INmune Bio Inc. operating margin by fiscal year
INmune Bio Inc. operating margin by fiscal year
DateOperating margin
FY2022-7013.5%
FY2023-18587.5%
FY2024-426400.0%
FY2025-61740.0%
LineFY2025
Operating expensesOperating Expense$30.9M
Research and developmentResearch And Development$20.7M
Total expensesTotal Expenses$30.9M
Pretax incomePretax Income-$45.9M

Learn while you research

Academy chapters picked for INmune Bio Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing257% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →